Canada Life’s ADMA Biologics ADMA Stock Holding History

Canada Life’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.52M	Sell	181,414 -14,369	-7%	-$131K	﹤0.01%	1268
2026 Q1	$1.76M	Sell	195,783 -10,447	-5%	-$165K	﹤0.01%	1189
2025 Q4	$3.76M	Sell	206,230 -45,692	-18%	-$770K	0.01%	875
2025 Q3	$3.7M	Sell	251,922 -1,621	-0.6%	-$27.8K	0.01%	958
2025 Q2	$4.62M	Sell	253,543 -5,919	-2%	-$121K	0.01%	822
2025 Q1	$5.14M	Sell	259,462 -17,109	-6%	-$296K	0.01%	776
2024 Q4	$4.74M	Sell	276,571 -3,937	-1%	-$74.1K	0.01%	866
2024 Q3	$5.61M	Buy	280,508 +203,515	+264%	+$3.16M	0.01%	807
2024 Q2	$860K	Buy	76,993 +22,944	+42%	+$192K	﹤0.01%	1533
2024 Q1	$357K	Buy	54,049 +28,832	+114%	+$158K	﹤0.01%	1749
2023 Q4	$113K	Hold	25,217	–	–	﹤0.01%	1921
2023 Q3	$90K	Buy	25,217 +17,225	+216%	+$66.3K	﹤0.01%	1983
2023 Q2	$30K	Hold	7,992	–	–	﹤0.01%	2075
2023 Q1	$26K	Hold	7,992	–	–	﹤0.01%	2163
2022 Q4	$31K	Buy	+7,992	New	+$24.7K	﹤0.01%	2170
2015 Q3	–	Sell	-1,040	Closed	-$9K	–	2439
2015 Q2	$9K	Buy	+1,040	New	+$8.99K	﹤0.01%	2537

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Canada Life's ADMA Position: Q2 2026 in Review

Canada Life reduced its ADMA Biologics (ADMA) stake by 7.3% in Q2 2026, selling an estimated $131K and leaving 181,414 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #1268.

Canada Life first reported a position in ADMA in Q2 2015 and has held it in 16 quarters since. The position peaked at $5.61M in Q3 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Canada Life held 181,414 shares of ADMA Biologics worth $1.52M as of Q2 2026.
Canada Life sold 14,369 ADMA Biologics shares in Q2 2026, an estimated $131K.
ADMA Biologics made up ﹤0.01% of Canada Life's portfolio in Q2 2026, its #1268 holding.
Canada Life first reported a position in ADMA Biologics in Q2 2015 and has held it in 16 quarters since.
Canada Life's ADMA Biologics position peaked at $5.61M in Q3 2024.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Canada Life's 13F filing for Q2 2026, filed 13 Aug 2026.